10-K · March 9, 2026
Coherus Oncology has completed a strategic pivot to an exclusive oncology focus (name change on May 29, 2025) and launched its FDA‑approved PD‑1 product LOQTORZI in the U.S. (launched Jan 2, 2024). Revenue accelerated…
Earnings analysis · 10-Q
CHRS earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Coherus Oncology's Q1 2026 results showed an EPS loss of $(0.25), beating estimates of $(0.27), while revenue of $12.31 million fell short of the $14.35 million estimate. The growth largely stemmed from LOQTORZI, which…
Read full summary
Coherus Oncology's Q1 2026 results showed an EPS loss of $(0.25), beating estimates of $(0.27), while revenue of $12.31 million fell short of the $14.35 million estimate. The growth largely stemmed from LOQTORZI, which generated $11.8 million in revenue, marking significant year-over-year growth despite seasonal challenges.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.25
- Segment
- LOQTORZI: $11.8M
What stood out
-
EPS Beat Estimate
Reported EPS was $(0.25) vs. estimate of $(0.27), a positive surprise of 0.0741.
-
Revenue Growth in LOQTORZI
LOQTORZI revenue was $11.8 million, up from $7.3 million YoY, a growth of 61%.
-
Lower SG&A Expenses
SG&A expenses decreased to $23.1 million from $26 million YoY.
-
Improved Cash Position
Cash, cash equivalents, and marketable securities were $167 million, down from $172 million, indicating financial stability.
-
Free Cash Flow Down
Free cash flow was $(57.9) million, compared to $(25.8) million YoY, reflecting higher cash burn.
-
Cash from Financing
Net cash provided by financing activities was $53.6 million due to stock issuance.
What to watch
-
Revenue Miss vs. Estimates
Revenue was $12.31 million, missing estimates of $14.35 million, leading to concerns about growth rates.
-
High Operating Cash Drain
Operating cash flow was $(57.9) million, significantly higher cash burn compared to $(25.8) million YoY.
-
Default on Convertible Notes
The risk of default on the substantial $51.64 million debt, including the 2026 Convertible Notes.
Management's outlook
Outlook deferred to future reports; management expects revenues in 2026 to increase.
Earlier filings 4
10-Q · May 12, 2025
Coherus reported continuing-operations net revenue of $7,599 (thousand) in Q1 2025, up from $2,308 (thousand) in Q1 2024 driven by LOQTORZI. Gross margin expanded to 65% (from 38%) but the company remains unprofitable…
10-K · March 6, 2023
Coherus (CHRS) positions itself as a biosimilars commercial platform funding a build-out of an immuno‑oncology franchise. Key near-term commercial assets include UDENYCA (pegfilgrastim) with 2022 net sales of $203.8…
10-Q · August 4, 2022
Coherus reported Q2 2022 revenue of $60.151 million, down from $87.643 million in Q2 2021, and a GAAP net loss of $50.150 million (loss per share $0.65). Management reiterated near-term headwinds from increased…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.